The diet drug Belviq is being withdrawn from the US market because a Belviq safety clinical trial shows an increased occurrence of cancer cases. This February 2020 Belviq FDA Drug Safety Communication announced the Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, and noted that excess cases of pancreatic cancer, colon cancer, rectal cancer, and lung cancer were observed.
The FDA approved Belviq as a weight-loss drug in 2012.
The Belviq safety clinical trial leading to this February 2020 Belviq recall is the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients – Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) clinical trial.
In connection with this Belviq recall we are investigating possible Belviq lawsuits involving for patients who have been diagnosed with cancer, including but not limited to:
Of course, we will continue to monitor the medical research for more information about the specific types of cancer cases associated with Belviq.[View article at original source]